News
VRNA
16.09
-2.48%
-0.41
Weekly Report: what happened at VRNA last week (0318-0322)?
Weekly Report · 3d ago
Weekly Report: what happened at VRNA last week (0311-0315)?
Weekly Report · 03/18 10:12
Weekly Report: what happened at VRNA last week (0304-0308)?
Weekly Report · 03/11 10:10
Strong Buy Recommendation on Verona Pharma Backed by Positive Phase III Results and Robust Commercial Strategy
TipRanks · 03/08 12:56
Verona Pharma Price Target Maintained With a $32.00/Share by HC Wainwright & Co.
Dow Jones · 03/04 12:19
HC Wainwright & Co. Reiterates Buy on Verona Pharma, Maintains $32 Price Target
Benzinga · 03/04 12:09
Buy Rating Affirmed on Verona Pharma Ahead of Ensifentrine’s Expected FDA Approval and Strong Financial Standing
TipRanks · 03/04 11:29
Weekly Report: what happened at VRNA last week (0226-0301)?
Weekly Report · 03/04 10:12
Andrew Fisher Joins Verona Pharma as General Counsel
Barchart · 03/04 01:00
Medical marijuana market expected to grow at 22% CAGR through 2027
Medical marijuana market expected to grow at 22% CAGR through 2027. The market for medical marijuana products is estimated to expand at a compound annual growth rate of 21.9% internationally. Medical marijuana is used to relieve clinical symptoms such as pain and epilepsy. North America is expected to contribute 47% to the growth over the forecast period.
Seeking Alpha · 03/02 18:04
Verona Pharma Price Target Maintained With a $33.00/Share by Wedbush
Dow Jones · 03/01 13:46
Wedbush Reiterates Outperform on Verona Pharma, Maintains $33 Price Target
Benzinga · 03/01 13:37
Truist Financial Sticks to Their Buy Rating for Verona Pharma (VRNA)
Verona Pharma has an analyst consensus of Strong Buy, with a price target of $28.32. The company has a one-year high of $23.81 and a low of $11.83. Verona Pharma is developing a drug for the treatment of respiratory diseases. Truist Financial analyst Joon Lee reiterated a Buy rating on the stock.
TipRanks · 03/01 12:35
Buy Rating Affirmed: Verona Pharma’s Promising Future with Ensifentrine and Expanding R&D Pipeline
Analyst Andreas Argyrides from Wedbush reiterated a Buy rating on the stock and has a $33.00 price target. Verona Pharma’s progress with ensifentrine, a drug designed to treat a range of respiratory diseases including COPD, is in the final stages of FDA approval.
TipRanks · 03/01 12:06
Verona Pharma’s New Share Price & Shareholder Rights Risk – A Cause for Worry?
TipRanks · 03/01 06:03
Verona Pharma Non-GAAP EPS of -$0.02
Seeking Alpha · 02/29 07:50
Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Barchart · 02/29 01:00
Earnings Preview For Verona Pharma
Verona Pharma is set to give its latest quarterly earnings report on Thursday, 2024-02-29. Analysts estimate the company will report an earnings per share of $-0.26. Last quarter the company beat EPS by $0.12. Shares of Verona Pharma were trading at $17.91 as of February 27.
Benzinga · 02/28 17:01
Verona Pharma Q4 2023 Earnings Preview
Seeking Alpha · 02/28 15:50
Notable earnings before Thursday's open
Seeking Alpha · 02/28 15:23
More
Webull provides a variety of real-time VRNA stock news. You can receive the latest news about Verona Pharma through multiple platforms. This information may help you make smarter investment decisions.
About VRNA
Verona Pharma Plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine, is an investigational, inhaled, small molecule and selective, dual phosphodiesterase 3 and 4 (PDE3 and PDE4) inhibitor. This dual inhibition enables it to act as a bronchodilator and a non-steroidal anti-inflammatory agent . It is engaged in developing inhaled ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD). The Company's two additional formulations of ensifentrine are in Phase II development for the treatment of COPD: dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). The Company's wholly owned subsidiary is Verona Pharma, Inc.